Karyopharm and Menarini's Nexpovio (selinexor) Receive EC's Marketing Authorisation for the Treatment of Multiple Myeloma
Shots:
- The EC has granted marketing authorization for Nexpovio in combination with bortezomib (qw) and SVd for MM who have received one prior therapy
- The approval was based on the P-III (BOSTON) study to evaluate the efficacy, safety & health-related QoL parameters of selinexor, bortezomib, and dexamethasone (SVd) as qw vs twice-weekly bortezomib & dexamethasone (Vd) in 402 adult patients which showed that qw SVd resulted in a significant reduction in risk of disease progression or death over twice-weekly Vd regimen
- The marketing authorization is valid in all 27 member states of the EU, Iceland, Liechtenstein, Norway & Northern Ireland. Stemline will be responsible for all commercialization activities in the EU
Ref: PRNewswire | Image: Karyopharm
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.